Showing results (1-10 of 4,089) with videos related to
Sort By:
Pageof 409
Signal Transduction and Targeted Therapy|August 17, 2023
Immunotherapy in hematologic malignancies: achievements, challenges and future prospectsLu Tang, Zhongpei Huang, Heng Mei, et al.Frontiers in Immunology|December 17, 2020
Controlling Cytokine Storm Is Vital in COVID-19Lu Tang, Zhinan Yin, Yu Hu, et al.Biomed Research International|March 17, 2021
T Cell Exhaustion and CAR-T Immunotherapy in Hematological MalignanciesLu Tang, Yinqiang Zhang, Yu Hu, et al.Military Medical Research|November 8, 2023
Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancerLu Tang, Zhong-Pei Huang, Heng Mei, et al.Annals of Hematology|October 9, 2023
IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapyXindi Wang, Chenggong Li, Wenjing Luo, et al.Cytotherapy|April 19, 2023
Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphomaWenjing Luo, Chenggong Li, Jianghua Wu, et al.Platelets|October 16, 2019
Fibrinogen levels are associated with bleeding in patients with primary immune thrombocytopeniaMin Xu, Lili Luo, Mengyi Du, et al.Heliyon|May 23, 2022
A multicompartment mathematical model based on host immunity for dissecting COVID-19 heterogeneityJianwei Li, Jianghua Wu, Jingpeng Zhang, et al.Journal of Cancer|February 6, 2019
Prognostic and Clinicopathological Significance of MiR-155 in Hematologic Malignancies: A Systematic Review and Meta-analysisLu Tang, Yi-Zhong Peng, Cheng-Gong Li, et al.Blood Cancer Journal|April 24, 2023
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignanciesYinqiang Zhang, Chenggong Li, Mengyi Du, et al.Pageof 409